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Anti-inflammation induced by counter-irritation or by treatment with
non-steroidal agents inhibits the growth of a tumour of non-detected
immunogenicity
D.O. Sordelli, P.A. Fontan, R.P. Meiss, R.A. Ruggiero & O.D. Bustuoabad
Instituto de Investigaciones Hematologicas, Academia Nacional de Medicina, Buenos Aires, Argentina.
Summary Counter-irritation (CI) triggered by different non-specific irritant stimuli delayed the growth of a
murine tumour of non-detected immunogenicity. The syngeneic LB tumour transplant by itself also induced
CI and decreased the number of leukocytes migrating to a secondary s.c. irritant stimulus, e.g. sponge or
carrageenan. On the other hand, partial inhibition of cell migration by treatment with either 0.5 mg kg'
indomethacin or 0.3 mg kg-' piroxicam retarded LB tumour growth, presumably by a mechanism unrelated to
inhibition of immune responses by PGE2. It is suggested that Cl may play a role in the early stages of
concomitant resistance.
Activated macrophages (MO) can display cytotoxicity against
tumour cells and are considered an important host defence
mechanism against neoplasia. However, M4s may play a
dual role in the growth of solid angiogenesis-dependent
tumours (Folkman, 1985) since their presence at the site of
incipient neoplastic growth is essential for neo-
vascularisation. Although the mechanisms involved remain
obscure, a regulatory effect of inflammation on different
stages of tumour growth has been proposed (Normann et al.,
1988). In support of this hypothesis, Prehn & Prehn (1987)
suggested that immunogenic neoplastic cells may benefit from
interaction with inflammatory Mos. Furthermore, it has been
reported that treatment with non-steroidal anti-inflammatory
agents (NSAIA) may restrict the growth of tumours of vary-
ing degrees of immunogenicity, probably by inhibiting pros-
taglandin E2 synthesis (Goodwin & Ceuppens, 1983).
Physiological anti-inflammation is mediated by complex and
not completely understood mechanisms. One of these, CI,
was defined as the ability of local irritation to exert an
anti-inflammatory effect at a remote site in the body (Atkin-
son & Hicks, 1975). CI is non-specific and, as recently sug-
gested, may inhibit the growth of immunogenic tumours
(Normann et al., 1985b, 1987). This study was aimed at
investigating the effect of CI and the administration of
NSAIA on the growth of a solid tumour on non-detected
immunogenicity.
Materials and methods
Animals
Male and female 8-week-old F, hybrids (Balb/c x DBA/2)
were raised in our animal house under standard conditions
and fed ad libitum with Cargill (Buenos Aires) pelleted food
and acidified tap water (final concentration, 50 mM HCI,
pH = 2.8).
Tumour
The T-helper cell leukaemia (LB), which arose spontaneously
in a 6-month-old Balb/c male mouse (Ruggiero et al., 1985)
was, at the beginning of this study, in its 58th s.c. passage.
When LB cells are injected s.c. a solid tumour develops in
situ. Infiltration of lymph nodes, spleen and liver can be
demonstrated at autopsy, but no solid metastases are
detected. The LB cells were obtained from a solid tumour of
a mouse inoculated s.c. 10 days before with 107 cells. The
tumour mass was removed, cut into small pieces and forced
through a wire mesh. Cells were suspended in Hanks
Balanced Salt Solution (HBSS) without calcium and
magnesium (Flow Laboratories, McLean, VA, USA) to the
appropriate density. Cell viability was assessed by trypan
blue exclusion. Suspensions containing fresh cells were
inoculated s.c. in the lateral flank and tumour growth was
evaluated every other day by measuring tumour length and
width with calipers. Tumour volume was determined using
the formula proposed by Attia & Weiss (1966): V = 0.4 x D
x d2 (V, tumour volume in mm3, D and d, longest and
shortest diameters). The LB tumour exhibited no detectable
immunogenicity in a rejection assay for Balb/c mice (Rug-
gierro et al., 1985). Previous work from our laboratory has
shown that the number of animals bearing a tumour and
survival were not modified by immunisation of F, (Balb/c x
DBA/2) s.c. with irradiated LB cells (data not shown).
Anti-inflammatory treatment
Indomethacin N-methyl-D-glucamine solution (IM 75, Mont-
pellier, Buenos Aires) was diluted in 0.01 SM NaCl to obtain a
dose of 0.5 mg kg-' in 0.2 ml. Piroxicam (Pfizer, Argentina)
was dissolved in dimethylsulphoxide, diluted 1 in 10 in O.IM
sodium bicarbonate, and further diluted in 0.01SM NaCl to
obtain the appropriate doses in 0.2 ml.
Induction and evaluation ofcounter-irritation
CI was triggered by implanting a nylon sponge (8-O mm3)
s.c., or inoculating 108 heat-killed Pseudomonas aeruginosa
s.c. The effect of this treatment was compared with the CI
produced by inoculating 106 LB cells s.c. CI was evaluated by
determining the inhibition of both oedema and cell migration
induced by the inflammatory stimuli. Inhibition of oedema
was evaluated 5 h after injecting 50 ll 1% carrageenan
(Sigma Chemical Co., St Louis, MO, USA) into one of the
hind-footpads. The degree of oedema was evaluated by
weighing the amputated hind limbs. (Oyanagui, 1984). Cell
migration was determined by s.c. implantation of a
thoroughly washed, sterile polystyrene sponge either 24 h
after administration of the irritant stimulus or at different
times after tumour cell challenge. Twenty-four hours after
implantation the sponge was removed, migrating cells were
squeezed out and the total cell count was determined (Bar-
rera et al., 1985). Inhibition of cell migration was also
measured histopathologically in mice challenged s.c. with 106
LB cells. At different times mice were injected intradermically
(i.d.) wiht 20 jtl of 1% carrageenan in the contralateral flank
and killed 24 h later. Skin explants were fixed with 8%
buffered formalin and tissue slices were stained with
Haematoxylin and Eosin by standard procedures.
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Figure 1 Modulation of tumour growth by counter-irritation
induced by a sponge implanted s.c. 24 h before challenge with 106
LB cells. Each point represents the median from six mice,
(*) P<0.01 compared with controls.
Statistics
Statistical analysis was performed using the Epistat package
(T.L. Gustafson, Round Rock, TX, USA) in a personal
computer. Data with normal distribution and homogeneous
variances were compared by analysis of variance using the
ANOVA program. Otherwise, data were analysed by the
rank sum test using the Ranktest program.
Results
To determine whether CI affected tumour growth in vivo, a
polystyrene sponge was implanted s.c. to generate local
inflammation, followed 24 h later by 106 tumour cells s.c. in
the contralateral flank. Tumour growth was delayed (Figure
1) but tumour incidence and survival rates were not modified.
Tumour growth was also retarded by anti-inflammatory
treatment (Figure 2) and death of the mice (Table I) was
delayed by 10 days. The tumour grew in all eight control
mice while it didn't grow in two out of eight piroxicam-
treated mice. When treatment with piroxicam was continued
beyond day 24 after tumour challenge, the solid tumour
never developed although most animals died due to general-
ised infiltration by LB cells. In another experiment, 5-day-old
tumours developing from a 106 cell inoculum were excised,
and the weight determined in untreated (3.38 ± 0.27 g) and
piroxicam-treated (1.25 ± 0.09 g) mice. The number of cells
recovered from tumours of control mice was 2.0 x 108 while
1.3 x 108 cells were recovered from tumours of treated mice.
The smaller size of the tumours in treated mice, conse-
quently, does not seem to be related to a decrease in tumoral
oedema due to anti-inflammatory treatment. Moreover,
incubation of the tumour mass at 60°C until constant weight
revealed that the weight loss was 67% in untreated and 83%
in treated mice, which indicates that the water relative con-
tent was higher in treated than in control mice.
The effects on inflammation of either CI triggered by
different irritants or NSAIA treatment were evaluated by
Table I Effect of piroxicam on mice survival after s.c. inoculation of
LB tumour cells
Control Piroxicam
Days surviving/total surviving/total P
20 7/8 8/8 1
24 6/8 8/8 0.450
26 1/8 8/8 0.002
30 1/8 7/8 0.012
42 0/8 2/8 0.450
0
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Figure 2 Inhibition of tumour growth by treatment with pirox-
icam. Animals were treated i.p. with 0.3 mgkg-' piroxicam for
24 days, starting 72 h before challenge with 105 LB cells. Each
point represents the median from six mice, (*) P<0.01 when
compared with controls.
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Figure 3 Hind-paw oedema induced by carrageenan injection
and cells migrating towards a secondary sponge placed s.c., in
mice treated with 0.3 mg kg-' piroxicam, 0.5 mg kg-' indometh-
cin and mice with a primary s.c. sponge. Control mice were
injected i.p. with saline and the group receiving a primary sponge
were, in addition, sham-inoculated with a trocar. Since neither
paw oedema nor cell migration were affected by this procedure,
the results from a single control group are exhibited. Each bar
represents the arithmetic mean ± s.e.m. from eight mice,
(*) significant difference (see level of significance in Results).
determining (i) the degree of oedema inhibition of the hind-
limb footpads and (ii) the inhibition of cell migration
towards the site where a second irritative stimulus was
delivered. Carrageenan-induced paw oedema was inhibited by
an s.c. implanted sponge (P = 0.029). A single dose of pirox-
icam 0.3 mg kg-' or indomethacin 0.5 mgkg-' also inhibited
paw oedema (P = 0.0006 and P = 0.0002, respectively)
(Figure 3). Cell migration towards a second s.c. sponge was
diminished by treatment with piroxicam (P = 0.0043) or
indomethacin (P = 0.0079). The presence of the first s.c.
sponge as the primary irritant decreased the number of cells
recovered from the contralateral, second s.c. sponge
(P = 0.0086) (Figure 3). CI induced by an s.c. injection of
2 x 10' formalin-killed gram-negative bacteria (Pseudomonas
aeruginosa) also decreased the number of migrating cells
from (1.5 ± 0.1) x 106 (control mice) to 6.5 x I05 cells ml-'
(P = 0.0086).
The presence of LB tumour exerted anti-inflammatory
activity as measured by decrease of paw oedema and cell
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Figure 4 The effect of an LB solid tumour on oedema induced
by carrageenan injection in the hind-footpad (a), and on cell
migration into the sponge implanted s.c. (b). Mice bearing a
tumour were evaluated after challenge with 106 and 107 LB cells
respectively. Each point represents the arithmetic mean ± s.e.m.
from eight mice, (*) significant difference when compared with
controls (see text for level of significance). Shaded areas represent
the arithmetic mean ± s.e.m of the hind limb weight of (a), and
the cell number retrieved from (b) unchallenged mice.
migration. Paw oedema was diminished on day 4 or 6 after
inoculation of 106 LB cells (P = 0.0069) when compared with
controls (Figure 4a). The number of cells recovered from the
sponges were decreased by days 5 and 6 after tumour
implantation (P = 0.029 and P = 0.0004, respectively). On
day 7 a rebound effect was observed and the number of cells
was increased (P = 0.029) (Figure 4b).
The effect of the tumour on cell migration towards an
inflammatory i.d. stimulus (carrageenan) was confirmed his-
tologically. In control mice, microscopy of skin explants
revealed inflammation characterised by diffuse infiltration
involving dermis and subcutaneous fatty tissue (Figure 5a).
The infiltrate contained predominantly mononuclear cells
(inset of Figure Sa). In contrast, mice bearing a solid LB
tumour of 7 days growth exhibited inflammation in a band
pattern restricted to a thin layer localised between dermis and
fatty subcutaneous tissue (inset Figure 5b). When car-
rageenan was administered to mice bearing a 10-day tumour,
severe inflammation developed, with intense infiltration
localised in a band between dermis and fatty subcutaneous
tissue, with only diffuse infiltration in these two areas (Figure
Sc). At higher magnification, the density of the mononuclear
cell infiltrate was even greater than that seen in untreated
mice (inset Figure Sc vs. inset Figure Sa).
Discussion
There are two main aspects to be discussed in the light of the
results from this study. One relates to CI as a natural
mechanism of tumour growth inhibition, and the other is the
therapeutic application of NSAIA to obtain inhibition of
Figure 5 Histopathological analysis of skin explants from the
area where 1% carrageenan was injected intradermally to control
mice (a), mice bearing a 7-day-old solid LB tumour (b) and mice
bearing a 10-day-old solid LB tumour (c) (magnification x 2.5).
The insets depict, at higher magnification ( x 25) the infiltrated
region of the tissue in each case. Representative photomicro-
graphs from groups of six mice are shown.
non-immunogenic tumour growth. Inhibition of
inflammation by a secondary irritant stimulus due to CI has
been demonstrated in diverse experimental systems. Suppor-
ting our results, there is previous evidence suggesting that
inflammatory responses may be affected by the presence of a
tumour. Snyderman et al. (1976) showed that experimental
transplantation of a benzopyrene-induced sarcoma in rats
prevented M4 accumulation during inflammation. Further-
more, Normann et al. (1985a) have shown that transplanta-
tion of syngeneic tumour cells depressed MO inflammatory
responses, probably through an increase in the endogenous
levels of corticosterone (Normann et al., 1988). Our data
demonstrate that, as with immunogenic tumours, a cancer of
immunogenicity below our level of detection can also induce
CI.
At least two important features of tumour-M4 interaction
should be considered. The first is that cellular immune res-
ponses occurring within a tumour can destroy it (Zbar et al.,
1970). In fact, immunologically mediated tumour killing is
frequently associated with an influx of MO to the site of
neoplastic growth (Shin et al., 1975). On the other hand,
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migratory cells, especially MO, are required during the early
stages of solid tumour growth (Folkman & Cotran, 1976).
There were two significant findings in our study: (i) inhibition
of tumour growth by an inflammatory focus located away
from the site of LB cell grafting; and (ii) inhibition of blood
cell migration induced by the LB tumour towards the site
where an irritant Htad been inoculated. Because the LB
tumour itself can both induce CI and be affected by anti-
inflammation, it would be expected that a primary tumour
inoculum could also inhibit the growth of a secondary
inoculum of the same tumour.
Inhibition ofexperimental metastases by a primary tumour
has been observed in laboratory animals (Gorelik et al.,
1978) and defined as 'concomitant immunity' (Gorelik et al.,
1981) or, more appropriately, 'concomitant resistance' (Meiss
et al., 1986), a non-specific, rapid, dose-dependent and com-
plex phenomenon. The molecular basis of concomitant resis-
tance remains unknown, but it is speculated that several
mechanisms may be acting either simultaneously or sequen-
tially. It has been demonstrated in our laboratory that,
although non-immunogenic, the LB tumour can induce con-
comitant resistance (Ruggiero et al., 1985), and that inhibi-
tion of secondary LB tumour growth by the presence of a
primary tumour is abrogated if inflammatory M4s are
injected into the secondary site of tumour cell implantation
(Bustuoabad et al., 1984). We detected inhibition of cell
migration induced by an LB tumour for a 4-5 day period,
coinciding with the early stages of concomitant resistance. If
our finding is correct, CI may therefore explain the early
inhibition of a secondary inoculum of LB cells; once the
non-immunogenic neoplastic tissue is organised and vas-
cularised, secondary tumour growth would not be affected by
inhibition ofMO migration induced by either CI or treatment
with NSAIA.
Administration of different NSAIAs as a single agent to
inhibit tumour growth has been attempted (Humes et al.,
1974; Lynch et al., 1978; Bennet et al., 1979, 1982, 1985;
Narisawa et al., 1981; Panje, 1981; Pollard & Luckert, 1981;
McCormick & Moon, 1983; Caignard et al., 1984; Fulton,
1984; Rubio, 1984; McCormick et al., 1985; Kort et al.,
1986). Piroxicam treatment inhibits colon carcinogenesis
(Pollard & Luckert, 1983; Reddy et al., 1987) in rats, and in
combination with an anti-neoplastic agent it has also been
used in man (Braun et al., 1987). The conflicting results
obtained in these studies may be because of (i) a wide variety
of spontaneous and induced tumours used experimentally; (ii)
the tumours being transplanted in different sites; (iii) different
animal species being used; (iv) NSAIA treatment being
started at different times, before or after tumour challenge;
and (v) NSAIAs being administered alone or in combination
with other drugs (Caignard et al., 1984). The major trend
from these studies, however, is that NSAIA can inhibit
tumour growth. Because high levels of PGE2 secreted by
immunogenic tumours can interfere with immune responses
against tumour cells (Normann et al., 1987), it has been
postulated that the anti-tumour activity of NSAIAs may be
partly due to restoration of immune functions following
inhibition of PGE2 synthesis (Lynch et al., 1978; Robertson
et al., 1988). Other mechanisms which may explain the anti-
tumour activity of NSAIAs include inhibition of blood cell
migration, as shown in this study, and the ability of NSAIAs,
including piroxicam, to form stable copper complexes (Weser
et al., 1982), an important angiogenic factor necessary for
neovascularisation (Ziche et al., 1982).
It can be concluded that a syngeneic tumour of non-
detected immunogenicity can induce CI, which may play a
role in the early stages of concomitant resistance, and that
treatment with NSAIA delays LB tumour growth in vivo.
Further studies ar required to ascertain the usefulness of
NSAIA treatment to prevent or delay the appearance of
metastases.
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